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Abstract 
 
Ascidians, especially those belonging to the Ascidiidae, are known to 
accumulate extremely high levels of vanadium in vanadocytes, one type of blood 
(coelomic) cell.  Vanadium, which exists in the +5 oxidation state in seawater, is 
accumulated in the vanadocytes and reduced to the +3 oxidation state.  We have 
been trying to characterize all of the polypeptides specific to vanadocytes and to 
specify the proteins that participate in the accumulation and reduction of 
vanadium.  To date, we have localized three enzymes in vanadocytes: 6-
phosphogluconate dehydrogenase (6-PGDH: EC 1.1.1.44), glucose-6-phosphate 
dehydrogenase (G6PDH: EC 1.1.1.49), and glycogen phosphorylase (GP: EC 
2.4.1.1), all of which are involved in the pentose phosphate pathway.   In the 
current study, we cloned a cDNA for transketolase, an essential and rate-
limiting enzyme in the non-oxidative part of the pentose phosphate pathway, 
from vanadocytes.  The cDNA encoded a protein of 624 amino acids, which 
showed 61.8% identity to the human adult-type transketolase gene product.  By 
immunocytochemistry and immunoblot analyses, the transketolase was revealed 
to be a protein that was expressed only in vanadocytes and not in any of the 
more than ten other types of blood cell.  This finding, taken together with the 
localized expression of the other three enzymes, strongly supports the hypothesis 
that the pentose phosphate pathway functions exclusively in vanadocytes. 
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1.Introduction 
 
Ascidians, known as tunicates or sea squirts (Chordata, Urochordata, 
Ascidiacea), accumulate extremely high levels of vanadium in vanadocytes, one 
of their approximately ten types of blood cell [1-5].  The vanadium concentration 
in vanadocytes can reach 350 mM, corresponding to 107 times the level in 
seawater, where vanadium is dissolved at a concentration of 35 nM [6, 7].  This 
is thought to be the highest rate of concentration of a metal in any living 
organisms.  Vanadium, a multivalent transition metal, is generally present in 
the biosphere in the +5, +4, and +3 oxidation states [8, 9].  Vanadium dissolved 
in seawater usually occurs as vanadate anions in the +5 oxidation state (V(V)) 
[10], whereas most vanadium in vanadocytes is reduced to the +3 oxidation state 
(V(III)) with a small amount in the +4 oxidation state (V(IV)) [11-17].  Some 
reducing agents must, therefore, be involved in the reduction and accumulation 
of vanadium in ascidian blood cells.  In vitro experiments have shown that some 
biologically relevant reducing agents can reduce V(V) to V(IV), including 
ascorbate [18], cysteine [19, 20], norepinephrine [21], and glutathione [22].  
However, no information has been obtained on the reducing agents that 
participate in the reduction in ascidian vanadocytes. 
About ten years ago, we prepared several monoclonal antibodies to 
distinguish vanadocytes from the other types of blood cell.  During the course of 
these experiments, a monoclonal antibody, S4D5, recognized a 45 kDa antigen 
specific to the cytoplasm of vanadocytes [23].  This was revealed to be 6-
phosphogluconate dehydrogenase (6-PGDH: EC1.1.1.44) based on cDNA isolation 
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of RNA samples from the blood cells of the ascidian by immunoscreening [24].  
6-PGDH from the pentose phosphate pathway is localized massively in 
vanadocytes.  Therefore, we examined whether other enzymes related to the 
pentose phosphate pathway are also localized in vanadocytes.  As a result, two 
other enzymes related to the pentose phosphate pathway were also revealed to 
be exclusively and strongly expressed in vanadocytes by immunocytochemistry 
and by measuring enzymatic activity [25, 26].  One is glucose-6-phosphate 
dehydrogenase (G6PDH: EC1.1.1.49), the first enzyme of the pentose phosphate 
pathway.  The other is glycogen phosphorylase (GP: EC 2.4.1.1), which catalyzes 
the phosphorylation of glycogen to produce glucose 1-phosphate, which is further 
interconverted into glucose 6-phosphate, the first substrate in both the pentose 
phosphate and Embden-Meyerhof pathways. 
The pentose phosphate pathway consists of an oxidative part and a 
nonoxidative part.  The oxidative part converts glucose 6-phosphate to ribulose 
5-phosphate and CO2, and at the same time generates NADPH for use in 
reductive biosynthesis.  The nonoxidative part isomerizes ribulose 5-phosphate 
to xylulose 5-phosphate and ribose 5-phosphate, which are converted into 
fructose 6-phosphate and glyceraldehyde 3-phosphate by a sugar rearrangement 
system.  Therefore, the present study examines whether transketolase (TKT: 
EC2.2.1.1), the rate-limiting enzyme of the nonoxidative part of this pathway, is 
also exclusively localized in vanadocytes.  It is worthwhile that the pentose 
phosphate pathway is fully functional in vanadocytes, because the coexistence of 
enzymes in the pentose phosphate pathway and high levels of vanadium in 
vanadocytes implicate the pathway in the reduction and accumulation of 
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vanadium by ascidians. 
 
2. Materials and Methods 
 
2.1 PCR amplification  
 
A cDNA library of blood cells of Ascidia sydneiensis samea has been 
constructed in Uni-Zap XR vector (Stratagene, La Jolla, USA) [24].  Lambda 
phage DNA was extracted from the amplified cDNA library.  Degenerate 
primers were designed from the conserved amino acid sequences of 
transketolases of several animals.  The forward primer was 5'- AT(A/C/T) 
GG(A/C/G/T) GA(A/G) GA(A/C/T) GG(A/C/G/T) CC -3' and the reverse one was 5'-
CC (A/G)TC (A/C/G/T)(C/G)(A/T) (A/C/G/T)GG (A/G)TA (A/G)AA (A/C/G/T)AC -3'.  
PCR conditions were as follows: 0.2 μg lambda phage DNA, 200 pmole each 
primer, 0.2 mM dNTP, 25 mM Tris-HCl (pH 8.3), 50 mM KCl, and 1.5 mM MgCl2.  
The reaction volume was 50 μl.  30 cycles of PCR were run; each cycle consisted 
of 94°C for 45 sec, 50°C for 45 sec, and 72°C for 45 sec.  This was followed by a 
final extension at 72°C for 5 min.  Amplified DNA fragments of the expected 
length were directly cloned into pBluescript vector at the EcoRV site with T-
overhangs. 
 
2.2 Screening the cDNA library 
 
The same cDNA library was screened with digoxigenin-labeled random-
primed DNA probes derived from the cloned PCR fragments.  Hybridization was 
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done at 65°C for at least 16 hrs in 0.25 M disodium hydrogen phosphate buffer 
(Na-Pi buffer, pH 7.2), 7% SDS, 1 mM EDTA, and 10 ng/ml probes.  The 
membranes were washed three times in 20 mM Na-Pi buffer (pH 7.2), 1% SDS at 
65°C.  They were treated with anti-digoxigenin-AP conjugate (F. Hoffmann-La 
Roche Ltd, Switzerland).  The signals were detected by chemiluminescence with 
CSPD substrates (F. Hoffmann-La Roche Ltd) and Hyper-ECL film (Amersham 
Pharmacia Biotech, Sweden).  Positive plaques were screened repeatedly until 
they were cloned.  The cDNAs were excised as plasmids in vivo according to the 
manufacturer’s protocol.  Nucleotide sequences were determined using a 
ThermoSequenase dye-prime sequencing kit and an ALFexpress automated 
sequencer (Amersham Pharmacia Biotech). 
 
2.3 Preparation of anti-transketolase antiserum 
 
The partial fragment of ascidian transketolase cDNA that corresponded 
to the amino acid residues from the 27th to the 264th residue (Fig. 1, double 
arrows) was amplified from cDNA clone #106 with the following primers: 
Forward, 5'- GGA ATT CAT TCT GTC TAC T -3'; Reverse, 5'- GGT CGA CTC 
AAG ATA CAG GTT TCC -3'.  The amplified cDNA fragment was cloned in the 
EcoRV site of pBluescript SK(-) vector, and the nucleotide sequence was 
confirmed to be the same as the corresponding part of cDNA clone #106.  The 
cDNA fragment was excised by EcoRI and SalI, and ligated into the 
corresponding site of pMAL-c2 plasmid vector (New England Biolabs, Inc., MA, 
U.S.A.).  By nucleotide sequence determination, the open reading frame of the 
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ascidian transketolase was confirmed to be continuous with that of maltose 
binding protein (MBP).  The resulting plasmid was designated pTKT-MBP. 
Six ml of an overnight culture of E. coli TB1 cells transformed with 
pTKT-MBP were diluted in 250 ml LB medium supplemented with 100 μg/ml 
ampicillin and 0.3 mM IPTG, and then cultured at 37°C for 6 hrs.  The cells 
were pelleted, suspended in lysis buffer (10 mM phosphate, 30 mM NaCl, 0.25% 
Tween20, 10 mM 2-mercaptoethanol, 10 mM EDTA, and 10 mM EGTA) 
containing 6M urea, and lysed with a sonicator (Vibra Cell; Sonic & Materials, 
Inc., CT, U.S.A.).  The solubilized protein fraction was recovered by 
centrifugation at 10,000 ×g for 10 min at 4°C, and dialyzed against 100 volumes 
of lysis buffer at 4°C overnight.  Then, the TKT-MBP fusion proteins obtained 
were purified with amylose resin according to the supplier’s protocol (New 
England Biolab, Inc.). 
One hundred micrograms of purified TKT-MBP fusion proteins were 
injected intraperitoneally into an 8-week-old female BALB/c mouse.  The 
injection was repeated two and four weeks after the first injection.  Three days 
after the last injection, blood was collected, allowed to stand at 37°C for 1 hr, and 
incubated at 4°C for 12 hrs.  The serum was removed from the clot, and any 
remaining insoluble material was removed by centrifugation at 10,000 ×g for 10 
min at 4°C.  The supernatant obtained was stored at -20°C. 
 
2.4 Immunoblotting and immunohistochemistry 
 
Immunoblot analysis and immunocytochemistry with anti-transketolase 
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antiserum were carried out as described previously (19, 20).  Briefly, the TKT-
MBP fusion proteins were electrophoresed and blotted onto a nitrocellulose 
membrane.  The antibodies were purified with the immobilized fusion proteins.  
The purified antibodies were used for both the immunoblot analysis and the 
immunocytochemistry at 4,000 and 1,000 times dilution calculated from the 
original antiserum, respectively.  For the immunoblot analysis, HRP-conjugated 
anti-mouse IgG antibodies (PI-2000; Vector, Inc., CA, U.S.A.) were used and the 
signals were detected with ECL reagents (Amersham Pharmacia Biotech).  
Fluorescein-labelled anti-mouse IgG antibodies were absorbed by fixed ascidian 
blood cells before use in immunocytochemistry. 
 
3. Results 
 
3.1 Cloning cDNAs for transketolase from ascidian blood cells 
 
Using a pair of degenerate primers corresponding to conserved amino 
acid sequences of known transketolase proteins, we amplified cDNA fragments 
related to a transketolase gene from an A. sydneiensis samea blood cell cDNA 
library.  Several amplified fragments were cloned, sequenced, and revealed to 
have almost identical nucleotide sequences (data not shown).  Using one of the 
PCR fragments as a probe, we isolated eight independent cDNA clones of a 
transketolase homologue out of 9×104 phages of the cDNA library of A. 
sydneiensis samea blood cells.  They contained almost identical nucleotide 
sequences, although their lengths varied from 1.1 kbp to 2.5 kbp.  We chose the 
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longest cDNA clone, #106, subcloned it by restriction digestion, and sequenced 
both strands of the subclones completely (Fig. 1).  The nucleotide length of 
cDNA clone #106 was 2,545 bp including the cloning sites (EcoRI at the 5' 
terminal and XhoI at the 3' terminal).  This is consistent with the apparent 
length of the transcript detected by Northern blot analyses (data not shown), 
suggesting that the cDNA clone corresponded to full-length mRNAs.  The cDNA 
contained a single, long open reading frame of 1,875 nucleotides including the 
termination codon, which encoded a protein of 624 amino acids (Fig. 1). 
The deduced amino acid sequence of ascidian cDNA clone #106 showed 
striking similarities to transketolases from various organisms (Fig. 2).  There 
was 61.8% amino acid identity between the ascidian and human adult-type 
transketolase sequences, and 61.7% identity between the ascidian and mouse 
transketolase sequences.  A thiamine diphosphate-binding motif and a 
transketolase motif, which were pointed out by Schenk et al. (23), were found in 
the predicted amino acid sequence of cDNA clone #106 (Fig. 2).  Within the 
transketolase motif, an NADH-binding-like motif was also completely conserved 
(Fig. 2).  The calculated molecular weight of the amino acid sequence predicted 
from cDNA clone #106 was 67.8 kDa, which is close to those of mammals 
(ranging from 67.7 to 67.8 kDa) and a nematode (66.0 kDa).  Therefore, we 
concluded that cDNA clone #106 corresponded to a transketolase homologue in A. 
sydneiensis samea. 
 
3.2 Expression of transketolase proteins in vanadocytes  
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More than ten types of blood cell have been distinguished in A. 
sydneiensis samea on the basis of their morphology.  These include hemoblasts, 
lymphocytes, leukocytes, pigment cells, morula cells, signet ring cells, 
compartment cells, small compartment cells, and giant cells [27-30].  Of these, 
signet ring cells have been revealed to be the vanadium-accumulating cells, also 
known as vanadocytes, and these generally account for more than 70% of the 
total blood cells [29, 31, 32].  To examine the localization of transketolase, we 
prepared a fusion protein of the N-terminal part of the ascidian transketolase 
and a maltose binding protein, in order to obtain anti-transketolase antiserum.  
The antiserum detected a single band of 65 kDa on Western blots of blood cell 
extracts of A. sydneiensis samea, showing good agreement with the expected 
molecular weight predicted from its nucleotide sequence (Figs. 3A, B).  By 
immunocytochemistry, the antiserum detected the transketolase protein only in 
the cytoplasm of signet ring cells (Figs. 4A, C).  No detectable protein was 
expressed in the other blood cells, demonstrating that the transketolase is 
exclusively expressed in the vanadocytes among the blood cells. 
 
4. Discussion 
 
The first clue to the exclusive localization of enzymes in the pentose 
phosphate pathway in vanadocytes was the identification of monoclonal antibody 
S4D5, which was prepared to distinguish vanadocytes from the approximately 
ten types of ascidian blood cell [23].  A 45-kDa antigen, recognized by S4D5 
monoclonal antibody, was found to localize in the cytoplasm of vanadocytes and 
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produce a clear band on SDS-PAGE of the homogenate of ascidian blood cells.  
The antigen was unexpectedly revealed to be 6-PGDH [24], which is generally 
thought to be expressed ubiquitously.  The specific expression of glucose-6-
phosphate dehydrogenase (G6PDH), another enzyme in the pentose phosphate 
pathway, in the cytoplasm of vanadocytes, has also been detected by both 
immunocytochemistry and enzymatic activity [25].  Furthermore, a 100 kDa 
antigen recognized by a newly prepared monoclonal antibody, S8E4, was 
exclusively localized in the cytoplasm of vanadocytes and identified as glycogen 
phosphorylase (GP), by sequencing the encoded cDNA [26].  The fact that 
glycogen phosphorylase and three other enzymes in the pentose phosphate 
pathway, including TKT found in this study, are abundant in the cytoplasm of 
vanadocytes, while undetectable in the other blood cells, suggests that the 
pentose phosphate pathway is closely linked with the reduction and 
accumulation of vanadium ions in vanadocytes. 
Most of the vanadium accumulated in ascidians is reduced to V(III), with 
a small amount of vanadium also present as V(IV) [12-17].  A consensus has 
been reached on the process of vanadium accumulation in ascidians.  First, 
vanadium dissolved in seawater as V(V) is accumulated in ascidians.  Then, the 
vanadium is reduced to V(IV) by some reducing agent contained in the ascidians.  
Finally, almost all the vanadium is accumulated in the vacuoles of vanadocytes 
in the cationic form of V(III) under high sulfate concentrations at an extremely 
low pH [32-35].  In the vacuoles, the vanadium seems to be in a free form and 
not bound to macromolecules. 
Thus, the pentose phosphate pathway is the major supplier of reducing 
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agents in the form of NADPH, and is tightly coupled to cellular processes that 
require NADPH and other reductase systems.  In fact, we have confirmed that 
NADPH directly reduces V(V) to V(IV) in vitro, in the presence of EDTA at 
neutral pH [36].  It is important to consider whether the reduction of V(V) 
observed in vitro occurs in vivo.  It is reasonable to assume that V(V) ion binds 
to a peptide or protein in the cytoplasm of ascidian vanadocytes.  We have 
isolated a vanadium-associated protein that is composed of at least 12.5 and 15 
kDa peptides from vanadocytes [37] and cloned the cDNA encoding these 
peptides (unpublished).  If such a peptide or protein plays the role that EDTA 
does in vitro, V(V) could be reduced to V(IV) directly by NADPH.  This 
assumption is likely true, since peptides and proteins bind more strongly to d1 
V(IV) ion than to d0 V(V) ion, according to known chemistry, and as a result V(V) 
species tend to be reduced more easily. 
TKT is known to be a rate-limiting enzyme of the pentose phosphate 
pathway.  Although essentially most types of cell in all organisms examined 
have this enzyme, its expression is regulated in accordance with its requirement.  
For example, transketolase activity in human white blood cells is extremely high, 
and a loss of its activity occurs in several diseases, such as a chronic lymphatic 
leucemia [38].  The activity is 100-200 times higher than that of red blood cells, 
suggesting the specific localization and function of pentose phosphate pathway in 
white blood cells.  Another example is that the mammalian cornea contains 
particularly high levels of TKT, consistent with the proposal that NADPH 
produced by the pentose phosphate pathway activity has a role in the removal of 
light-generated radicals [39-42].  Therefore, in ascidian vanadocytes, the specific 
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expression of TKT suggests an requirement for NADPH to reduce V(V) to V(IV). 
As shown schematically in Fig. 5, we have identified several proteins 
specific to vanadocytes.  Two polypeptides, of 58 and 45 kDa, have been 
identified as G6PDH and 6-PGDH, respectively [24, 25].  A 100 kDa protein has 
been identified as GP [26].  In addition, this study found that TKT in the 
pentose phosphate pathway was exclusively expressed in vanadocytes.  The 
localization of these enzymes strongly supports the hypothesis that the pentose 
phosphate pathway functions in vanadocytes and generates NADPH, which may 
be used as a reducing agent during the course of vanadium accumulation.  On 
the other hand, smaller molecules of 12.5, 15, and 16 kDa were identified as 
vanadium-associated proteins (VAPs) [37].  Their characterization is on going.  
The vanadium ions are accumulated in the vacuoles of vanadocytes, where 
protons and sulfate ions at extremely high concentration coexist with V(III) ions.  
We have already identified and cloned several subunits of a vacuolar-type proton 
ATPase localized in the vanadocytes [43, 44], and a search for other subunits and 
other membrane proteins is in progress. 
The exclusive presence of these peptides in vanadocytes has attracted our 
attention and must be the key to elucidating the mechanism of the unusual 
ascidian ability to accumulate vanadium at extremely high levels, which has 
never been reported in other living organisms, and reduce it to V(III). 
The function of the accumulated vanadium ions in the ascidian still 
remains to be explained.  Several researchers proposed that the vanadocytes use 
vanadium ions for the synthesis of tunic [48-53], while others proposed that the 
vanadium-containing vanadocytes may trap oxygen [54].  Another hypothesis is 
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proposed that vanadium ions may be used as antimicrobial agents [55-56].  
However, these proposals are not supported by sufficient experimental evidences. 
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Figure Legends 
 
 
Fig. 1.  (A) Restriction map of an ascidian transketolase cDNA clone.  Open 
bars show non-translated regions and the solid bar shows the coding region.  
The cDNA fragment corresponding to the 27th through 264th amino acid residues 
of the predicted protein was used for constructing pTKT-MBP plasmid (double 
arrows).  Scale bar, 500 bp.  (B) Nucleotide and amino acid sequences of the 
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cDNA clone.  Boxes show the restriction sites used for subcloning.  Regions 
corresponding to the PCR primers are shown by dotted lines.  The 
polyadenylation signal and poly (A) tail are doubly underlined.  The EcoRI 
linker is underlined.  These sequences are stored in the DDBJ, GenBank, and 
EMBL nucleotide databases under accession number AB016786. 
 
 
Fig. 2.  Alignment of the amino acid sequences of transketolases from various 
animals.  Identical residues are shaded.  A thiamine diphosphate (ThDP)-
binding motif and a transketolase motif are boxed.  Within the latter motif, the 
NADH-binding-like motif is shown in bold face.  Abbreviations: HA, human 
(Homo sapiens), adult-type isoform [45]; MM, mouse (Mus musculus) [46]; As, 
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ascidian (Ascidia sydneiensis samea) (this study); CE, nematode (Caenorhabditis 
elegans) [47]. 
 
 
Fig. 3.  Expression of transketolase proteins identified by anti-ascidian 
transketolase antiserum.  Lanes 1 and 4, 20 μg of whole cell extracts from blood 
cells of Ascidia sydneiensis samea; lanes 2 and 5, 10 μg of whole cell extracts of E. 
coli TB1 transformed with pTKT-MBP; lanes 3 and 6, 10 μg of whole cell extracts 
of E. coli TB1 transformed with pTKT-MBP after the induction of the expression 
of fusion proteins.  Samples were loaded and separated using 10% SDS-PAGE 
gels.  After electrophoresis, the gels were stained with Coomassie Brilliant Blue 
(lanes 1-3), or blotted on a nitrocellulose membrane and reacted with anti-
transketolase antiserum (lanes 4-6).  Note that 65-kDa transketolase proteins in 
the blood cells (lane 4) and 67-kDa TKT -MBP fusion proteins (lane 6) are 
detected by the anti-transketolase antiserum. 
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Fig. 4.  Immunocytochemistry of blood cells of A. sydneiensis samea.  The cells were fixed 
and reacted with (A, C) or without (B, D) the anti-transketolase antiserum.  The cells were 
then reacted with FITC-conjugated secondary antibody and observed with Nomarski 
microscopy (A, B) or fluorescent microscopy (C, D).  Note that staining was detected only 
in the signet ring cells (SRC, arrowheads), also known as vanadocytes, but not in the other 
blood cells such as giant cells (GC), morula cells (MC), or pigment cells (PC).  Some 
pigment cells show autonomous fluorescence.  Scale bar, 20 μm. 
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 Fig. 5.  A model for the pathway for the reduction and accumulation of 
vanadium in ascidian vanadocytes.  The vanadium taken into the vanadocytes 
is bound by vanadium-associated proteins (VAPs).  The pentose phosphate 
pathway exists in the vanadocytes and functions to generate NADPH, which may 
reduce V(V) to V(IV).  The V(IV) ions are transported into the vacuole and 
reduced to V(III) by unknown reductant(s).  The vacuole has an extremely high 
levels of H+ and SO42-.  Vacuolar proton ATPase (V-ATPase) accumulates 
protons in the vacuole.  Abbreviations: 6-PG, 6-phosphogluconate; 6-PGDH, 6-
phosphogluconate dehydrogenase (EC1.1.1.44); 6PGL, 6-phosphogluconolactone; 
E4P, erythrose 4-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-
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bisphosphate; G1P, glucose 1-phosphate; G6P, glucose 6-phosphate; G6PDH, 
glucose-6-phosphate dehydrogenase (EC1.1.1.49); GAP, glyceraldehyde 3-
phosphate; GP, glycogen phosphorylase (EC2.4.1.1); R5P, ribose 5-phosphate; 
Ru5P, ribulose 5-phosphate; S7P, sedoheptulose 7-phosphate; TKT, 
transketolase (EC2.2.1.1); Xu5P, xylulose 5-phosphate. 
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